Pharmacological augmentation of endothelium-derived nitric oxide synthesis

Journal of Managed Care Pharmacy

Volumn 13, Issue 5 SUPPL., 2007, Pages

  Bakris, Goerge L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Beta adrenergic receptors; Beta blockers; Hypertension; Nebivalol; Nitric oxide; Third generation beta blockers

Indexed keywords

ANTIHYPERTENSIVE AGENT; ARGININE; ATENOLOL; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; LABETALOL; LONG ACTING DRUG; METOPROLOL; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NEBIVOLOL; NITRIC OXIDE; NITRIC OXIDE INHIBITOR; PLACEBO; PROPRANOLOL; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ARTICLE; BLOOD PRESSURE; BRADYCARDIA; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MECHANISM; DRUG MEGADOSE; ESSENTIAL HYPERTENSION; HUMAN; INSULIN SENSITIVITY; INTRINSIC SYMPATHOMIMETIC ACTIVITY; JUXTAGLOMERULAR APPARATUS; KIDNEY; MONOTHERAPY; NONHUMAN; PROTEIN SECRETION; RISK BENEFIT ANALYSIS; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

EID: 34547396391     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.s5.9     Document Type: Article

References (18)

1. Volpe M., Tocci G, Pagannone E. Fewer mega-trials and more clinically oriented studies in hypertension research? The case of blocking the renin-angiotensin-aldosterone system. J Am Soc Nephrol. 2006;17:S36-S43.
2. Weber MA. The role of the new beta-blockers in treating cardiovascular disease. Am J Hypertens. 2005;18(12 pt 2):169S-176S.
3. Braunwald E, Zipes DP, Libby P. Heart Disease: A Textbook of Cardiovascular Medicine. 6th ed. New York: WB Saunders Co.; 2001.
4. Van de Water A, Janssens W, Van Neuten J, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol. 1988;11:552-63.
5. Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol. 1994;38:199-204.
6. Van Nueten L, Taylor FR, Robertson JI. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens. 1998;12:135-40.
7. Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B, Mancia G. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press Suppl. 2003;2:35-40.
8. Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92:344-48.
9. Georgescu A, Pluteanu F, Flonta ML, Badila E, Dorobantu M, Popov D. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. Eur J Pharmacol. 2005;508:159-66.
10. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation. 2003;107:2747-52.
11. Fortepiani LA, Ortiz MC, Atucha NM, Garcia-Estan J. Nebivolol ameliorates nitric oxide deficient hypertension. Sci World J. 2002;2:1676-84.
12. Skarfors ET, Lithell HO, Selinus I, Aberg H. Do antihypertensive drugs precipitate diabetes in predisposed men? BMJ. 1989;298:1147-52.
13. Samuelsson O, Hedner T, Berglund G, et al. Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in die Primary Prevention Trial Göteborg, Sweden. J Human Hypertens. 1994;8(4):257-63.
14. Mykkänen L, Kuusisto J, Pyörälä K, et al. Increased risk of non-insulin-dependent diabetes mellitus in elderly hypertensive subjects. J Hypertens. 1994;12:1425-32.
15. Grimm RH. Antihypertensive therapy: taking lipids into consideration. Am Heart J. 1991;122:910-18.
16. Weber MA. Hypertension with concomitant conditions: the changing role of beta-adrenoreceptor blockade. Am Heart J. 1991;121:716-23.
17. Superko HR, Haskell WL, Krauss RM. Association of lipoprotein subclass distribution with use of selective and non-selective beta-blocker medications in patients with coronary heart disease. Arteriosclerosis. 1993;101:1-8.
18. von Fallois J, Faulhaber HD. Nebivolol, a beta blocker of the 3rd generation: modern therapy of arterial hypertension. Results of a multicenter observation study [article in German], Schweiz Rundsch Med Prax. 2001;90:435-41.